Aerovate Therapeutics appoints Donald Santel to Board of Directors

Jade Biosciences, Inc.

Santel appointed as Class I director effective Jan 19, 2023; term expires at 2025 annual meeting.
He joins the Nominating and Corporate Governance Committee; other committees unchanged.
Santel brings over 40 years biopharma experience, including CoTherix and Hyperion (PAH focus) and Oyster Point Pharma.
He will receive standard non-employee director equity and cash compensation for 2023.
Board determined Santel is independent under Nasdaq listing standards.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donald J. Santel

Director

JBIO · Jade Biosciences, Inc.

Effective: 2023-01-19
Filed: January 23, 2023, 6:59 PM ET

Effective as of January 19, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Donald J. Santel as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Donald J. Santel was appointed as Director at Jade Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective as of January 19, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Donald J. Santel as a member of the Board.

View on SEC.gov

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.